Kairos Pharma Ltd. (NYSE American: KAPA) has announced favorable interim safety results from its ongoing Phase 1 clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (Tagrisso) for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who have developed resistance to osimertinib. The company reported that no Grade 3 or higher treatment-related adverse events have been observed among the 13 patients treated with ENV-105 to date, supporting continued advancement of the program toward an early efficacy readout.
ENV-105 is designed to inhibit CD105, a protein associated with acquired drug resistance, with the goal of restoring sensitivity to osimertinib. Osimertinib is the current standard of care for EGFR-mutated NSCLC, but resistance often develops, limiting its effectiveness. The Phase 1 study is evaluating the safety, tolerability, and recommended Phase 2 dose of the combination therapy, with all reported side effects manageable through standard supportive care. The company believes ENV-105 has the potential to extend the clinical utility of osimertinib by addressing acquired resistance after disease progression.
This news is significant because it addresses a critical unmet need in lung cancer treatment. EGFR-mutated NSCLC affects a substantial number of patients, and while osimertinib has improved outcomes, resistance remains a major challenge. If ENV-105 can successfully reverse resistance, it could provide a new treatment option for patients who have progressed on osimertinib, potentially improving survival and quality of life. The favorable safety profile in this interim analysis is encouraging, as it suggests the combination may be well-tolerated, which is essential for a patient population that often has limited treatment alternatives.
The implications for the industry are also substantial. Successful development of ENV-105 could establish CD105 as a key target for overcoming drug resistance in multiple cancer types. Kairos Pharma is already evaluating ENV-105 in a Phase 2 clinical trial for castrate-resistant prostate cancer, indicating the broader potential of this approach. For investors, positive data could enhance the value of Kairos Pharma's pipeline and attract further interest in CD105-targeted therapies.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. More information about the company and its pipeline can be found in its newsroom at https://ibn.fm/KAPA.
The full press release is available at https://ibn.fm/SmdwW.
